Laverdière Caroline, Liu Qi, Yasui Yutaka, Nathan Paul C, Gurney James G, Stovall Marilyn, Diller Lisa R, Cheung Nai-Kong, Wolden Suzanne, Robison Leslie L, Sklar Charles A
Department of Pediatrics, University of Montreal, Montreal, QC, Canada.
J Natl Cancer Inst. 2009 Aug 19;101(16):1131-40. doi: 10.1093/jnci/djp230. Epub 2009 Jul 31.
The 5-year survival rate for individuals with neuroblastoma is approaching 70%. Few data exist, however, on the long-term outcomes of these patients, who are often treated at a very young age.
Outcome data were obtained for 954 5-year neuroblastoma survivors who were diagnosed in 1970-1986 and enrolled in the Childhood Cancer Survivor Study (CCSS). Late mortality, second malignant neoplasms, and chronic health conditions were analyzed in relation to treatment factors using Poisson regression models and their modification with generalized estimating equations. Neuroblastoma survivors were compared with a cohort of 3899 siblings of CCSS participants for risk of chronic health conditions and selected sociodemographic outcomes. All statistical tests were two-sided.
Six percent of patients died more than 5 years after their diagnosis (standardized mortality ratio = 5.6; 95% confidence interval [CI] = 4.4 to 6.9). The most common causes of death were disease recurrence (n = 43) and second malignant neoplasms (n = 13). The cumulative incidence of second malignant neoplasms was 3.5% at 25 years and 7.0% at 30 years after diagnosis. Compared with the sibling cohort, survivors had an increased risk of selected chronic health conditions (risk ratio [RR] = 8.3; 95% CI = 7.1 to 9.7) with a 20-year cumulative incidence of 41.1%. The most prevalent outcomes involved the neurological, sensory, endocrine, and musculoskeletal systems, with 20-year cumulative incidences of 29.8%, 8.6%, 8.3%, and 7.8%, respectively. Neuroblastoma survivors who were treated with multimodality therapy were more likely to develop a chronic health condition than survivors treated with surgery alone (RR = 2.2; 95% CI = 1.6 to 3.0). Neuroblastoma survivors were less likely than siblings to have ever been employed (P = .04) or to be married (P < .001) and had a lower personal income (P = .009).
Neuroblastoma survivors have an increased rate of mortality and second malignant neoplasms, relative to the age- and sex-comparable US population, and of chronic health conditions, relative to their siblings, which underscores the need for long-term medical surveillance.
神经母细胞瘤患者的5年生存率接近70%。然而,关于这些通常在幼年时接受治疗的患者的长期预后的数据却很少。
获取了954名在1970年至1986年期间被诊断为神经母细胞瘤且参加了儿童癌症幸存者研究(CCSS)的5年幸存者的预后数据。使用泊松回归模型及其通过广义估计方程的修正,分析了晚期死亡率、第二原发性恶性肿瘤和慢性健康状况与治疗因素的关系。将神经母细胞瘤幸存者与CCSS参与者的3899名兄弟姐妹组成的队列进行比较,以评估慢性健康状况风险和选定的社会人口学结局。所有统计检验均为双侧检验。
6%的患者在诊断后5年以上死亡(标准化死亡率 = 5.6;95%置信区间[CI] = 4.4至6.9)。最常见的死亡原因是疾病复发(n = 43)和第二原发性恶性肿瘤(n = 13)。诊断后25年时第二原发性恶性肿瘤的累积发病率为3.5%,30年时为7.0%。与兄弟姐妹队列相比,幸存者患选定慢性健康状况的风险增加(风险比[RR] = 8.3;95%CI = 7.1至9.7),20年累积发病率为41.1%。最常见的结局涉及神经、感觉、内分泌和肌肉骨骼系统,20年累积发病率分别为29.8%、8.6%、8.3%和7.8%。接受多模式治疗的神经母细胞瘤幸存者比仅接受手术治疗的幸存者更有可能出现慢性健康状况(RR = 2.2;95%CI = 1.6至3.0)。神经母细胞瘤幸存者比兄弟姐妹就业的可能性更小(P = 0.04)或结婚的可能性更小(P < 0.001),且个人收入更低(P = 0.009)。
相对于年龄和性别匹配的美国人群,神经母细胞瘤幸存者的死亡率和第二原发性恶性肿瘤发生率增加,相对于其兄弟姐妹,慢性健康状况发生率增加,这突出了长期医学监测的必要性。